2024, health.osu.edu/wellness/exercise-and-nutrition/glp1-foods-to-limit#:~:text=Be%20careful%20if%20the%20volume,Recommended%20Read.
CMS can take a major step toward that goal by expanding coverage for semaglutide. The cosigning organizations are hopeful that CMS will take steps to expand coverage for semaglutide and other anti-obesity medications, preventing patients from developing life-threatening diseases
[6] [9] According to NICE guidance (NG28), GLP-1 receptor agonists are recommended as part of a comprehensive treatment strategy for type 2 diabetes that includes dietary modification, increased physical activity, and other glucose-lowering therapies when appropriate
Lets make our voices heard and protect patient access to critical treatments
In this case, examining the safety and efficacy of a combination therapy approach, higher doses, injectable administration or earlier intervention may be worthwhile
Bolanos, S